The estimated Net Worth of Ronald Manna is at least $1.4 million dollars as of 23 February 2015. Ronald Manna owns over 400 units of Misonix Inc stock worth over $968,047 and over the last 21 years Ronald sold MSON stock worth over $433,852.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronald Manna MSON stock SEC Form 4 insiders trading
Ronald has made over 10 trades of the Misonix Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Ronald sold 400 units of MSON stock worth $4,636 on 23 February 2015.
The largest trade Ronald's ever made was exercising 36,500 units of Misonix Inc stock on 13 November 2014 worth over $110,960. On average, Ronald trades about 4,131 units every 188 days since 2004. As of 23 February 2015 Ronald still owns at least 36,475 units of Misonix Inc stock.
You can see the complete history of Ronald Manna stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Ronald Manna's mailing address?
Ronald's mailing address filed with the SEC is 1938 NEW HIGHWAY, , FARMINGDALE, NY, 11735.
Insiders trading at Misonix Inc
Over the last 21 years, insiders at Misonix Inc have traded over $4,371,211 worth of Misonix Inc stock and bought 1,536,334 units worth $6,620,934 . The most active insiders traders include Stavros G. Vizirgianakis, Gary Gelman et Michael A Jr Mcmanus. On average, Misonix Inc executives and independent directors trade stock every 29 days with the average trade being worth of $378,885. The most recent stock trade was executed by Sharon W Klugewicz on 20 May 2020, trading 825 units of MSON stock currently worth $10,032.
What does Misonix Inc do?
Misonix, Inc. is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company's history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients.
What does Misonix Inc's logo look like?
Complete history of Ronald Manna stock trades at Misonix Inc
Misonix Inc executives and stock owners
Misonix Inc executives and other stock owners filed with the SEC include:
-
Stavros Vizirgianakis,
President, Chief Executive Officer, Director -
Charles Miner,
Independent Director -
Paul LaViolette,
Independent Chairman of the Board -
T Guy Minetti,
Director -
Patrick A Mc Brayer,
Director -
John Gildea,
Director -
Thomas M Patton,
Director -
Michael L Consilvio,
VP - Marketing -
Richard A Zaremba,
Vice President and CFO -
John Joseph Salerno,
VP, Quality & Regulatory -
Howard Alliger,
Director -
Daniel Voic,
VP-R&D and Engineering -
Joseph J Brennan,
Vice President, Operations -
Gary Gelman,
10% owner -
Michael A Jr Mcmanus,
President, CEO -
Michael Koby,
Director -
Christopher H Wright,
Vice President - U.S. Sales -
Capital Management, Llc1315...,
-
Gwendolyn A Watanabe,
Director -
Jonathan Jay Waggoner,
SVP, Wound Sales -
Thomas F Oneill,
Director -
Frank Napoli,
VP, Operations -
Michael C Ryan,
SVP, Medical Division -
W Paul Constantine,
SVP, Strat. Plan. & New Prod. -
Kenneth Coviello,
V.P - Medical Devices -
Ronald Manna,
VP-New Prod. Dev. & Reg. Aff. -
Bernhard Berger,
VP-Industrial/Scientific Prod. -
Allan Richard Staley,
President -
Linwood A. Staub,
Sr. VP Wound -
Robert S Ludecker,
SVP, Global Sales - Marketing -
Joseph P Dwyer,
Chief Financial Officer -
Pat Beyer,
Director -
Sharon W Klugewicz,
Chief Operating Officer